Third Harmonic Bio
Third Harmonic Bio raises $200M Series C at $750M valuation
Third Harmonic Bio: Series C Funding Round
Third Harmonic Bio has successfully raised $200M in Series C funding, reaching a valuation of $750M.
Company Overview
Dicerna-based RNAi therapeutics
Funding Details
The Series C round was led by ARCH Venture Partners, with participation from Polaris Partners, RA Capital Management, GV.
Company Information
- Headquarters: 325 Vassar Street, Cambridge, MA 02139
- Founded: 2019
- Employees: 100+
- Category: Biotech
Investment
Third Harmonic Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- ARCH Venture Partners: Verified investor in Series C
- Polaris Partners: Verified investor in Series C
- RA Capital Management: Verified investor in Series C
- GV: Verified investor in Series C
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free